7AC Stock Overview A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Acarix AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Acarix Historical stock prices Current Share Price SEK 0.02 52 Week High SEK 0.046 52 Week Low SEK 0.013 Beta 1.56 1 Month Change 19.39% 3 Month Change -6.64% 1 Year Change -1.50% 3 Year Change -66.67% 5 Year Change -81.93% Change since IPO -99.13%
Recent News & Updates
Acarix AB (publ), Annual General Meeting, May 15, 2025 Nov 12
New major risk - Revenue and earnings growth Nov 10
Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023) Nov 08
New major risk - Revenue and earnings growth Aug 26
Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023) Aug 23
Acarix Expands Within US Wellness Exam Market Aug 13 See more updates
Acarix AB (publ), Annual General Meeting, May 15, 2025 Nov 12
New major risk - Revenue and earnings growth Nov 10
Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023) Nov 08
New major risk - Revenue and earnings growth Aug 26
Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023) Aug 23
Acarix Expands Within US Wellness Exam Market Aug 13 Acarix AB (publ) announced that it expects to receive SEK 21 million in funding Jul 05
Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study Jun 13
Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 May 29
First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023) May 15
Acarix AB (publ) Approves Board Elections May 15
Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study Apr 11
High number of new and inexperienced directors Mar 01
Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022) Feb 16
Acarix Appoints New Members to the Advisory Board Feb 15 Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million. Feb 02
Acarix AB (publ) Announces CEO Changes Feb 01 Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024
Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network Nov 24
New major risk - Financial position Nov 14
Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022) Nov 10 Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million. Oct 19
Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022) Sep 01
Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor Aug 29
Acarix AB Elects Mikael Thorén as Director May 12
Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021) Apr 25
Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021) Feb 18
Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023 Feb 17 Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024
Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023 Feb 14
Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022 Nov 16
Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial Sep 29
Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021) Aug 26
Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022 Aug 22
First quarter 2022 earnings released: kr0.059 loss per share (vs kr0.083 loss in 1Q 2021) May 12
No independent directors Apr 29
Acarix AB (publ), Annual General Meeting, May 11, 2022 Apr 12
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 18
Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis Feb 10
Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System Feb 08
Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020) Nov 14
Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020) Aug 21
Director has left the company May 20
Director has left the company May 20
Director has left the company May 20
Chairman of the Board Werner Braun has left the company May 14
First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020) May 12
Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019) Apr 24
Director recently bought €87k worth of stock Apr 11
Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study Jan 14
Acarix Receives US Market Approval for the CADScor System Nov 26
Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR Nov 19
Third quarter 2020 earnings released: kr0.11 loss per share Nov 15 Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021
Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million. Sep 10
Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021 Aug 08
Earnings released Aug 07 Shareholder Returns 7AC DE Medical Equipment DE Market 7D 3.7% 5.1% 2.3% 1Y -1.5% -1.3% 11.9%
See full shareholder returns
Return vs Market: 7AC underperformed the German Market which returned 11.9% over the past year.
Price Volatility Is 7AC's price volatile compared to industry and market? 7AC volatility 7AC Average Weekly Movement 48.6% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7AC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7AC's weekly volatility has increased from 37% to 49% over the past year.
About the Company Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.
Show more Acarix AB (publ) Fundamentals Summary How do Acarix's earnings and revenue compare to its market cap? 7AC fundamental statistics Market cap €22.84m Earnings (TTM ) -€6.30m Revenue (TTM ) €495.50k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7AC income statement (TTM ) Revenue SEK 5.68m Cost of Revenue SEK 550.00k Gross Profit SEK 5.13m Other Expenses SEK 77.36m Earnings -SEK 72.23m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) -0.068 Gross Margin 90.31% Net Profit Margin -1,272.33% Debt/Equity Ratio 0%
How did 7AC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 12:24 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Acarix AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Savin Edison Investment Research Ludvig Svensson Redeye Filip Einarsson Redeye
Show 0 more analysts 
